The agency is slated to decide whether to grant accelerated approval to the drug for treating NSCLC patients with EGFR exon 20 insertion mutations by February 2027.
This study analyzes BRCA testing patterns in U.S. breast cancer patients, highlighting barriers and disparities in access to genetic testing and precision care.
The firm is anticipating approvals in 2026 to push Enhertu into earlier breast cancer indications and Datroway into ...
The Frost & Sullivan Institute (FSI) is pleased to unveil this year's recipients of the Visionary Leadership Best Practices Recognition. These individuals exemplify purpose-driven leadership, bold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results